GlobeNewswire·Nov 9, 2026, 7:00 AM ET

Editas Medicine Announces Third Quarter 2026 Results and Business Updates

EDIT

Editas Medicine received HREC approval to initiate the Phase 1/2 Strive study of EDIT-401 for hyperlipidemia in Australia.
New preclinical data presented at AHA Scientific Sessions showed ≥90 percent LDL-C reduction maintained over 10 months in non-human primates.
A second IND/CTA was accepted for the CD70 HD Allo CAR T program collaboration with Bristol Myers Squibb, triggering a milestone payment to Editas.
Cash, cash equivalents, & marketable securities totaled $190.2 million as of September 30, 2026, providing a runway into the second half of 2028.
Patient dosing for the Strive study is expected to begin in 2026 with initial safety data reported in Q1 2027.
Topline safety & efficacy results from Part 1 of the Strive study are expected in the second half of 2027.
Dan Ory, M.D., was appointed Chief Medical Officer to oversee clinical development strategy for EDIT-401 & the broader pipeline.
Net loss for the three months ended September 30, 2026, was $23.4 million compared to $25.1 million in the same period in 2025.
Collaboration revenue increased to $10.4 million for the quarter, primarily due to milestone payments from strategic partners.
Research & development expenses rose to $21.2 million, driven by higher sublicense fees & costs associated with EDIT-401 development.
General & administrative expenses increased to $13.5 million, largely due to higher intellectual property & patent-related fees.
Editas plans to present at the 9th Annual Evercore Healthcare Conference on November 30, 2026.

Company: Editas Medicine, Inc.
Keywords: Nasdaq:EDIT, Editas Medicine, Inc.